Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
IMA
Strong SellSinkerImageneBio, Inc. · Healthcare · United States · $61M · Avg Vol: $60K/d
15
StockRankGet insider-trade alerts
Q
32
V
36
M
27
P/E (TTM)
—
ROE
-82.7%
D/E
0.0x
Dividend %
—
COMPANY DESCRIPTION
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases.
FINANCIAL SUMMARY (USD)
| Year | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|
| Revenue | 8.0M | 3.5M | 0.8M | -68.3% | — | — | — | — |
| EPS | -2.87 | -4.33 | -9.64 | — | -4.73 | -3.31 | -4.31 | — |
| Shares | 11.2M | 11.2M | 11.2M | -0.0% | 11.4M | — | — | — |
| Debt | 1.0M | 8.0M | 3.0M | 74.0% | 1.9M | — | — | — |
| Equity | -126.1M | -160.6M | 133.1M | — | — | — | — | — |
| Op CF | -18.2M | -21.3M | -47.8M | — | -52.6M | — | — | — |
| Inv CF | -10.5M | 11.1M | -5.8M | — | — | — | — | — |
| Fin CF | 0.1M | 6.9M | 135.5M | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)-15.3%
SMA 50SMA 200
Close
$5.01
RSI (14)
25.7
52W High
$9.22
From 52W High
0.5%
SCORE BREAKDOWN
Quality
32
ROIC
-34.2%22.0
ROE
-82.7%11.5
GP/Assets
0.0%9.6
Op. Margin
0.0%38.1
FCF/Assets
-17.8%22.7
Piotroski
438.9
Int. Cover
—N/A
D/E Ratio
0.01x83.3
Current Ratio
21.47x96.4
Value
36
P/E (TTM)
—N/A
EV/EBITDA
1.4x25.0
P/FCF
—N/A
P/B
0.4x98.4
P/S
—N/A
Div Yield
—N/A
Momentum
27
52W High %
54%29.0
RS 6M
-29%29.4
SMA 50/200
0.93x39.0
EPS Rev 4W
-8.3%10.1
EPS Rev 12W
—N/A
EPS Improve
+9%26.7
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$61M
P/E (Forward)
-1.1x
Gross Margin
—
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of IMA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| IMA | ImageneBio, Inc.(you) | $61M | 15 | Strong Sell |
| INKT | MiNK Therapeutics, Inc. | $58M | 15 | Strong Sell |
| SER | Serina Therapeutics, Inc. | $62M | 14 | Strong Sell |
| HYFT | MindWalk Holdings Corp. | $65M | 14 | Strong Sell |
| ELOX | Eloxx Pharmaceuticals, Inc. | $52M | 15 | Strong Sell |
| HYPD | Hyperion DeFi, Inc. | $51M | 16 | Strong Sell |
| OSTX | OS Therapies Incorporated | $76M | 15 | Strong Sell |
| PMVP | PMV Pharmaceuticals, Inc. | $65M | 19 | Strong Sell |
| 4875.T | MediciNova, Inc. | $70M | 18 | Strong Sell |
| PLRX | Pliant Therapeutics, Inc. | $69M | 12 | Strong Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.3%